An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo. (8th May 2013)

• Record Type: Journal Article
• Authors: Li, Lihua; Wang, Yan; Chen, Jun; Cheng, Bi; Hu, Jiehua; Zhou, Yuehua; Gao, Xin; Gao, Liucun; Mei, Xifan; Sun, Meiyan; Zhang, Zhuomei; Song, Haifeng
• Other Names: Ríos José Luis Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2013(2013)
• Publication Date: 2013-05-08
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2013/423129
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Arginine is a semiessential amino acid required for the growth of melanoma and hepatocellular carcinoma, and the enzymatic removal of arginine by pegylated arginine deiminase (ADI) or arginase is being tested clinically. Here, we report a genetically engineered arginase FC fusion protein exhibiting a prolonged half-life and enhanced efficacy. The use of this enzyme to treat different tumor lines both inhibited cell proliferation and impaired cellular migration in vitro and in vivo . Our data reinforce the hypothesis that nutritional depletion is a key strategy for cancer treatment.